Key Highlights

  • During Friday's session on November 13, 2026, the stock was marked down 7.51% at USD 70.19, which backs out to a prior close near USD 75.89 (calculated). The October 30, 2026 close was USD 72.22 in market data.
  • Revenue for the third quarter, disclosed on November 2, 2026, totalled USD 411.5 million, rising 23%, while Gross Profit of USD 266.7 million produced a 64.8% gross margin.
  • Adjusted EBITDA came in at USD 25.6 million, compared with USD 1.5 million the prior year, and the net loss shrank to USD 14.9 million from USD 80.0 million a year ago.
  • The company lifted its 2026 Revenue range to between USD 1.60 billion and USD 1.605 billion, roughly 25% expansion, but kept its adjusted EBITDA target near USD 65 million.

A 7.51% Decline With No Company Trigger on Record

Tempus AI (NASDAQ:TEM) was quoted 7.51% lower at USD 70.19 on Friday, November 13, 2026, per market data. No company announcement explaining the move turned up among items dated November 11 to 13, so the percentage applies only to the live session. The most recent company event was the third-quarter report on November 2, 2026. The 52-week span, according to market data, stretches from USD 40.77 up to USD 91.83, and the stock closed at USD 72.22 on October 30 after dropping 7.22% that session, so sharp daily moves are not new here. A Market Value of about USD 13.03 billion appeared at the October 30 close, and holding the share count near 180.43 million, today's price points to around USD 12.7 billion (calculated).

Revenue Growth, a Narrower Loss and a Lifted Revenue Range

Tempus AI (NASDAQ:TEM) offers AI-powered precision medicine, among them genetic testing and licensing of its data to pharmaceutical developers. Revenue of USD 411.5 million grew 23%, gross profit increased 27% and adjusted EBITDA hit USD 25.6 million. The loss narrowed to USD 14.9 million, against USD 80.0 million a year earlier, and cash plus marketable securities totalled USD 854.4 million. The 2026 revenue range moved to USD 1.60 billion through USD 1.605 billion, roughly USD 1.6 billion at the midpoint, yet adjusted EBITDA guidance held near USD 65 million, meaning the higher Top Line brought no added profit guidance. Gross profit expanded faster than revenue, 27% against 23%, a gap the extract of the release does not explain by segment, though a published summary put data-unit growth near 33%.

Pharma Data Contracts and Persistent GAAP Losses

Tempus AI (NASDAQ:TEM) saw its multi-year data licence with Bristol Myers Squibb broadened on October 23, 2026 to run through 2031, and in October it unveiled tie-ups aimed at cancer and Alzheimer's drug work. Trailing net loss stood at USD 254.43 million in market data, with about 180.43 million shares outstanding. Risks include ongoing GAAP losses, reimbursement and regulatory exposure in testing, and reliance on pharma contracts. Several AI-linked stocks are among the day's decliners, but no confirmed sector driver for November 12 to 13 turned up, so the cause of today's drop remains unverified. Separately, the genetic testing arm Ambry Genetics introduced a whole-genome offering for rare conditions on October 13, per market data.

Where Things Stand

The 7.51% fall lacks an identified trigger and could simply track Volatility in stocks carrying an AI label, not company-specific developments. Tempus AI (NASDAQ:TEM) delivered 23% revenue growth, a narrower net deficit, positive adjusted EBITDA and a higher revenue range, while GAAP results remain in the red. Upcoming checkpoints include fourth-quarter results, renewals of pharma data licences and progress toward the adjusted EBITDA goal that was left unchanged.